OTC Opportunity in Cancer Care

Introduction

Jay Pharma plans to leverage the significant data and brand equity of Tikun Olam to create a line of over-the-counter (OTC) products for the management of certain symptoms of cancer and cancer treatment that may include:

  • Pain
  • Nausea
  • Lack of Appetite
  • Anxiety

Tikun Olam employs evidence-based medicine and other best practices and its products, including Avidekel™, Midnight™, and Erez™, have been studied in numerous medical trials. Tikun Olam patient databases include 12,000+ persons treated across a variety of conditions, with a primary focus on cancer care.

MedReleaf is a leading Canadian Licensed Producer that was acquired by Aurora Cannabis (TSE:ACB) in July 2018.
Building on a history of medical cannabis research in Israel, Tikun Olam USA offers Tikun Olam genetics through partnerships across the U.S.
Medifarm grows, processes, and distributes TIkun Olam’s proprietary medical cannabis strains in the Australian market.

Tikun Olam Partners in the U.S. (Tikun Pharma), Canada (MedReleaf), and Australia (MediFarm) have developed leadership positions in local markets.

The Cannabis Industry Lacks Data

In a 2017 report, the National Academy of Sciences noted that cannabis has both therapeutic value and public health risks, but that there is a systemic lack of research needed to properly evaluate cannabis-based therapies.

The National Academy of Sciences offered recommendations that include:

  • Improving Research Quality: Develop standards and benchmarks to guide cannabis research.
  • Addressing Research Gaps: Evaluate the short- and long-term health effects of cannabis use.
  • Improving Surveillance Capacity: Ensure sufficient data are available.
  • Addressing Research Barriers: Fully characterize the impact of regulatory barriers to cannabis research and propose strategies for supporting a comprehensive cannabis research agenda.

Data Supports the Use of Tikun Olam Products in a Palliative Cancer Setting

Soroka Medical Center researchers analyzed data from cancer patients treated with medical cannabis between 2015 and 2017. Data was gathered at Tikun Olam’s central cannabis clinic and included all cancer patients starting treatment between March 2015 and February 2017 (Schleiderab, European Journal of Internal Medicine, 2018).

  • Main symptoms requiring therapy were: sleep problems (78.4%), pain (77.7%), weakness (72.7%), nausea (64.6%), and lack of appetite (48.9%).
  • 51% of patients had a 8 out of 10 on the pain scale.
  • 17% of cancer patients were administered Avidekel.

Research suggest that cannabis as a palliative treatment for cancer patients appears to be a well tolerated option to help patients cope with the malignancy-related symptoms.

  • After six months, 36% discontinued opioid use and 10% decreased their dose.
  • 95.9% of patients reported improvement in their condition.

Schleiderab, European Journal of Internal Medicine, 2018

Symptoms Prevalence at Intake Versus at Six Months

Intake

Change at Six Month Follow-up

Total Symptom Disappeared Improvement No Change or Deterioration
Sleep Problems 2,329 (78.4%) 155 (16.7%) 655 (70.8%) 114 (12.3%)
Weakness and Fatigue 2,160 (72.7%) 84 (10.9%) 429 (55.9%) 255 (33.2%)
Digestion Problems 1,918 (64.6%) 199 (26.7%) 375 (50.3%) 171 (23.0%)
Anxiety and Depression 1,694 (57.0%) 62 (10.1%) 455 (74.1%) 97 (15.8%)
Nausea and Vomiting 1,662 (56.0%) 251 (36.3%) 378 (54.7%) 62 (9.0%)
Lack of Appetite 1,453 (48.9%) 130 (25.8%) 313 (62.1%) 61 (12.1%)
Movement Limitation 1,051 (35.4%) 24 (7.5%) 134 (41.6%) 164 (50.9%)
Paresthesia 1,043 (35.1%) 60 (16.2%) 185 (50.0%) 125 (33.8%)
Dizziness 939 (31.6%) 97 (28.4%) 171 (50.1%) 73 (21.4%)
Dry Mouth 928 (31.2%) 89 (27.1%) 82 (25.0%) 157 (47.9%)